Cardiac Biomarkers Market Research Report - Global Forecast till 2027

Global Cardiac Biomarkers Market Research Report: By Type (Myocardial muscle Creatine Kinase, Troponins, Myoglobin, Brain Natriuretic Peptide, IMA), By Location of Testing (Point of Care Testing, Laboratory Testing) and By Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, Atherosclerosis) – Forecast to 2027

ID: MRFR/HC/7122-HCR | February, 2021 | Region : Global

Market Forecast


Cardiac Biomarkers Market is expected to cross USD 4236.02 Million by 2025 at a CAGR of 16.36%.


Cardiac biomarkers are protein molecules released into the bloodstream from heart muscle damaged by a blocked artery. These enzymes are measured to have an idea of how much muscle damage has been done. These biomarkers are specially used to help diagnosis, evaluate, and monitor patients with suspected acute coronary syndrome (ACS).


The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global cardiac biomarkers market. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.


 Market Synopsis


Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of these conditions and also helps monitor and manage someone with ACS and cardiac ischemia.


Troponin T and I, CK-MB, and myoglobins are most commonly in the evaluation of acute coronary syndrome. Out of this troponin T and I are the markers of choice for detecting the heart damage. However, other cardiac biomarkers are less specific for heart and may be elevated in other conditions like severe muscle injury, liver disease, and kidney disease.


The increasing incidence of cardiac diseases and related conditions are strongly motivating market players to introduce new efficient technologies in the market.


Market Influencers


High prevalence of cardiac disorders and increasing participation of market players are actively facilitating the growth of the cardiac biomarkers market. In September 2019, Abbott received FDA clearance for ARCHITECT STAT High Sensitivity Troponin-I blood test. This troponin diagnostic test will be used to detect heart attacks faster and more accurately than contemporary troponin tests.


Market Drivers



  • High prevalence of raised blood pressure: Raised blood pressure is the leading risk factor for cardiovascular disease. The prevalence of this troponin T blood pressure in adults aged 18 years and over was around 24.1% in men and 20.1% in women in 2015

  • Increasing adoption of outsourcing services

  • Growing technological advancements:

  • High spending by the pharmaceutical industry

  • The increasing popularity of POC cardiac testing kits

  • Increasing affordability for advanced cardiac treatments


Market Restraints



  • Chances of false diagnosis of myocardial infarction

  • High cost of the procedure

  • Presence of other efficient methods for the diagnosis of cardiovascular diseases


Cardiac Biomarkers Market Segmentation


By Type



  • Myocardial muscle Creatine Kinase (CK-MB): CK-MB has been the gold standard for detecting myocardial necrosis. After myocardial infarction, elevated CK-MB levels appear within 3- 8 hours, peaking within 9-30 hours and levels return to normal after 48- 72 hours



  • Troponins (T and I): The most important characteristic of this biomarker is its apparent absolute cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death



  • Myoglobin: Myoglobin is a low molecular weight heme protein is rapidly released into the circulation and is the first marker to exhibit raising levels after myocardial infarction



  • Brain Natriuretic Peptide (BNPs) or NT-proBNP: This biomarker is secreted primarily by the ventricular myocardium in response to wall stress. It is a very useful prognostic indicator in acute coronary syndrome



  • Ischemia Modified Albumin (IMA): This novel marker is produced when circulating serum albumin contacts ischemic heart tissues. IMA can be measured by the Albumin Cobalt Binding assay that is based on IMA's ability to bind to cobalt.


By Location of Testing



  • Point of Care Testing: Point of care testing expected to witness significant growth in the forecast period due to its increasing popularity



  • Laboratory Testing: Laboratory testing segment dominated the global cardiac biomarkers market. Increasing demand for cardiovascular disease diagnostics is boosting the revenue of this segment


By Application



  • Acute Coronary Syndrome: This segment holds the largest share owing to the increasing cases of this condition. It is a medical emergency that requires prompt diagnosis and care.



  • Congestive Heart Failure: It is a chronic progressive condition that affects the pumping power of your heart muscles



  • Myocardial Infarction: Approximately 1.5 million cases of myocardial infarction occur annually in the US region.



  • Atherosclerosis: Atherosclerosis is a disease in which plaque builds up inside your arteries. Cardiac troponins are used to assess the prognosis of patients presenting with atherosclerosis


By Region



  • Americas: The largest regional market. High prevalence of cardiac diseases is strongly expanding the US cardiac biomarkers market. As per the data suggested by the Centers for Disease Control and Prevention (CDC), around 610,000 people die of heart disease in the US every year. Also, coronary heart disease (CHD) is the most common type of heart disease, killing over 370,000 people annually.



  • Europe: Europe has some of the best healthcare services in the world, and rising participation of market players is strongly boosting the Europe cardiac biomarkers market. For instance, in October 2019, Novartis received FDA approval for Entresto for the treatment of symptomatic heart failure in pediatric patients aged one year and older.



  • Asia-Pacific: The fastest-growing regional market for Cardiac Biomarkers, Asia-Pacific, has the world’s largest population and fast-developing healthcare industry. Rising affordability for the advanced cardiac treatments and increasing disposable incomes are strongly impacting the growth of the Cardiac Biomarkers market in the region



  • Middle East & Africa: The Middle East & Africa has been primarily bifurcated into two regions—the Middle East and Africa. The presence of favorable government initiatives and recent healthcare reforms and developing healthcare infrastructure in the Middle East is expected to augment the market growth over the forecast period.


Key Players



  • Abbott Laboratories (US)

  • ACS Biomarker (The Netherlands)

  • BD (Becton, Dickinson and Company) (US)

  • bioMérieux SA (France)

  • Bio-Rad Laboratories, Inc. (US)

  • Danaher Corporation (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Johnson and Johnson (US)

  • Quidel Corporation (US)

  • Randox Laboratories Limited (UK)

  • Siemens AG (Germany)

  • Thermo Fisher Scientific, Inc. (US)

  • Trivitron Healthcare Pvt. Ltd. (India)

  • Novartis (Switzerland)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE

6.1. Overview

6.2. Myocardial muscle Creatine Kinase (CK-MB)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Troponins (T and I)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Myoglobin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Brain Natriuretic Peptide (BNPs) or NT-proBNP

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Ischemia Modified Albumin (IMA)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.7. ALT/AST

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.8. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING

7.1. Overview

7.2. Point of Care Testing

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Laboratory Testing

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION

8.1. Overview

8.2. Myocardial Infarction

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Congestive Heart Failure

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Acute Coronary Syndrome

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5. Atherosclerosis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

11. COMPANY PROFILES

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Product Type Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. ACS Biomarker

11.2.1. Company Overview

11.2.2. Product Type Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. BD (Becton, Dickinson and Company)

11.3.1. Company Overview

11.3.2. Product Type Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. BioMérieux SA

11.4.1. Company Overview

11.4.2. Product Type Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Bio-Rad Laboratories, Inc.

11.5.1. Company Overview

11.5.2. Product Type Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Danaher Corporation

11.6.1. Company Overview

11.6.2. Product Type Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. F. Hoffmann-La Roche Ltd

11.7.1. Company Overview

11.7.2. Product Type Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Johnson and Johnson

11.8.1. Company Overview

11.8.2. Product Type Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. QUIDEL CORPORATION

11.9.1. Company Overview

11.9.2. Product Type Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Randox Laboratories Limited

11.10.1. Company Overview

11.10.2. Product Type Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Siemens AG

11.11.1. Company Overview

11.11.2. Product Type Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Thermo Fisher Scientific, Inc.

11.12.1. Company Overview

11.12.2. Product Type Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Trivitron Healthcare Pvt. Ltd.

11.13.1. Company Overview

11.13.2. Product Type Overview

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. Others

12. APPENDIX

12.1. References

12.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL CARDIAC BIOMARKERS MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL CARDIAC BIOMARKERS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 10 US: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 12 US: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 13 CANADA: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 15 CANADA: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: CARDIAC BIOMARKERS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CARDIAC BIOMARKERS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CARDIAC BIOMARKERS MARKET

FIGURE 4 GLOBAL CARDIAC BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 5 GLOBAL CARDIAC BIOMARKERS MARKET SHARE, BY LOCATION OF TESTING, 2020 (%)

FIGURE 6 GLOBAL CARDIAC BIOMARKERS MARKET SHARE, BY APPLICATION, 2020 (%)

FIGURE 7 GLOBAL CARDIAC BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: CARDIAC BIOMARKERS MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: CARDIAC BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL CARDIAC BIOMARKERS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS

FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 17 ACS BIOMARKER: KEY FINANCIALS

FIGURE 18 ACS BIOMARKER: SEGMENTAL REVENUE

FIGURE 19 ACS BIOMARKER: REGIONAL REVENUE

FIGURE 20 BD (BECTON, DICKINSON AND COMPANY): KEY FINANCIALS

FIGURE 21 BD (BECTON, DICKINSON AND COMPANY): SEGMENTAL REVENUE

FIGURE 22 BD (BECTON, DICKINSON AND COMPANY): REGIONAL REVENUE

FIGURE 23 BIOMÉRIEUX SA: KEY FINANCIALS

FIGURE 24 BIOMÉRIEUX SA: SEGMENTAL REVENUE

FIGURE 25 BIOMÉRIEUX SA: REGIONAL REVENUE

FIGURE 26 CLINQUEST GROUP B.V.: KEY FINANCIALS

FIGURE 27 CLINQUEST GROUP B.V.: SEGMENTAL REVENUE

FIGURE 28 CLINQUEST GROUP B.V.: REGIONAL REVENUE

FIGURE 29 DANAHER CORPORATION: KEY FINANCIALS

FIGURE 30 DANAHER CORPORATION: SEGMENTAL REVENUE

FIGURE 31 DANAHER CORPORATION: REGIONAL REVENUE

FIGURE 32 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 33 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 34 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 35 JOHNSON AND JOHNSON: KEY FINANCIALS

FIGURE 36 JOHNSON AND JOHNSON: SEGMENTAL REVENUE

FIGURE 37 JOHNSON AND JOHNSON: REGIONAL REVENUE

FIGURE 38 QUIDEL CORPORATION: KEY FINANCIALS

FIGURE 39 QUIDEL CORPORATION: SEGMENTAL REVENUE

FIGURE 40 QUIDEL CORPORATION: REGIONAL REVENUE

FIGURE 41 RANDOX LABORATORIES LIMITED: KEY FINANCIALS

FIGURE 42 RANDOX LABORATORIES LIMITED: SEGMENTAL REVENUE

FIGURE 43 RANDOX LABORATORIES LIMITED: REGIONAL REVENUE

FIGURE 44 SIEMENS AG: KEY FINANCIALS

FIGURE 45 SIEMENS AG: SEGMENTAL REVENUE

FIGURE 46 SIEMENS AG: REGIONAL REVENUE

FIGURE 47 THERMO FISHER SCIENTIFIC, INC.: KEY FINANCIALS

FIGURE 48 THERMO FISHER SCIENTIFIC, INC.: SEGMENTAL REVENUE

FIGURE 49 THERMO FISHER SCIENTIFIC, INC.: REGIONAL REVENUE

FIGURE 50 TRIVITRON HEALTHCARE PVT. LTD.: KEY FINANCIALS

FIGURE 51 TRIVITRON HEALTHCARE PVT. LTD.: SEGMENTAL REVENUE

FIGURE 52 TRIVITRON HEALTHCARE PVT. LTD.: REGIONAL REVENUE




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.